Skip to main content

Moderna Value Stock - Dividend - Research Selection

Moderna, Inc

ISIN: US60770K1079, WKN: A2N9D9

Market price date: 05.08.2022
Market price: 186,84 USD

Moderna, Inc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 28-02-2022
Cash flow
Net operating cash flow 13.620.000.000
Capital Expenditures -284.000.000
Free cash flow 13.336.000.512
Balance sheet
Total Equity
Liabilities & Shareholders equity 24.669.000.000
Income statement
Net income
Eps (diluted) 28,310
Diluted shares outstanding 434.000.000
Net sales/revenue 18.471.000.000

Fundamental ratios calculated on: 05-08-2022

Key figures 05-08-2022
Cash flow
P/C 5,95
P/FC 6,08
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization81.088.561.152,00 USD
CountryUnited States
Indices,S&P 500,NASDAQ 100
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


BioNTech reports strong first half, expects demand to grow

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Prediction: This Bear Market Will Test Your Resolve In (At Least) 3 Ways

With the S&P 500 Index dipping as low as 23% within the past couple of months, we've hit the ballpark of bear market territory. Let's learn about three of the most common ways that bear markets create the very powerful temptation to sell so that you can resist the temptation when it calls. The most visible way that the bear market is likely to test investors' resolve is by demolishing the stocks of companies that were not too long ago put forward as high-flying success stories.

Where Will Moderna Be in 1 Year?

The vaccine maker has lost a little more than half of its value over the trailing 12-month period, partly because many investors think sales of its coronavirus vaccine, Spikevax, will drop off a cliff after this year. The coming 12 months could be crucial for Moderna, but what will they have in store for the company? In the U.S., the Biden Administration warned that a wave of the coronavirus is expected during the fall and winter.

Wall Street Breakfast: What Moved Markets

Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.

Moderna : Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission FORM 4 Check this box if no longer... | August 5, 2022

Official U.S. tally of new cases may be declining, but at-home testing obscures data; Novavax opens trial of vaccine for very young children

The daily average for new U.S. cases may have started to decline based on official numbers, but it's unclear at this time if the trend is real as so many people are testing at home and the data are not being captured.

Moderna's Unaddressed Grey Area

Moderna's pipeline won't be able to deliver on the timeline CEO Stéphane Bancel has set forth. MRNA's ever-expanding expenses will come back to haunt them in the next few fiscal years.

Factbox-Latest on the worldwide spread of the coronavirus

North Korea said on Friday all of its fever patients have recovered, its first such claim since the outbreak of the pandemic in the isolated economy, according to state media KCNA.

Dr. Fauci: You’ll ‘get into trouble’ if you’re not up to date on COVID vaccines and boosters — here are 3 stocks that could get a shot in the arm

These stocks might give your portfolio a boost.

Moderna Inc. stock outperforms market on strong trading day

Shares of Moderna Inc. advanced 4.12% to $194.18 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ...